phenol
acid
main
activ
ingredi
flo
lonicera
extract
possess
strong
antibacteri
antioxid
antivir
effect
content
higher
larg
ingredi
flavon
absolut
bioavail
oral
significantli
low
signific
low
influenc
clinic
efficaci
oral
prepar
present
studi
vitro
cell
situ
singlepass
intestin
perfus
vivo
pharmacokinet
studi
perform
investig
effect
co
intestin
absorpt
phenol
acid
pharmacolog
effect
antivir
activ
improv
co
verifi
mdck
cell
damag
inhibit
rate
influenza
viru
propag
observ
vitro
cell
show
absorpt
phenol
acid
flo
lonicera
extract
could
improv
co
meanwhil
co
low
medium
high
concentr
caus
signific
concentrationdepend
increas
p
app
valu
phenol
acid
compar
control
group
p
safe
cell
observ
singlepass
intestin
perfus
situ
model
show
intestin
absorpt
phenol
acid
enhanc
co
meanwhil
absorpt
enhanc
effect
phenol
acid
might
satur
differ
intestin
site
pharmacokinet
studi
co
dosag
mgkg
improv
bioavail
phenol
acid
flo
lonicera
extract
greatest
extent
safe
gastrointestin
morpholog
observ
besid
treatment
flo
lonicera
extract
co
dosag
mgkg
prevent
mdck
cell
damag
upon
influenza
viru
propag
better
control
find
suggest
co
dosag
mgkg
might
safe
effect
absorpt
enhanc
improv
bioavail
phenol
acid
antivir
activ
vitro
flo
lonicera
extract
flo
lonicera
flower
lonicera
japonica
possess
antibacteri
antiinflammatori
antivir
antiendotoxin
blood
fat
reduc
antipyret
etc
wide
use
tradit
chines
medicin
treat
exopathogen
windheat
epidem
febril
diseas
sore
carbuncl
furuncl
infect
diseas
wang
also
employ
extens
prevent
treat
seriou
viral
diseas
human
veterinari
sasr
coronaviru
swine
flu
viru
call
bouvardin
jiao
flo
lonicera
extract
extract
lonicera
japonica
wide
use
chines
medicin
prepar
shang
et
al
jin
yin
hua
san
jin
yin
hua
oral
liquid
shuanghuanglian
freezedri
powder
inject
shuanghuanglian
oral
liquid
yinqiao
capsul
yinqiaojiedu
tablet
etc
extens
use
treat
acut
upper
respiratori
tract
infect
caus
viru
bacteri
infect
clinic
practic
oral
prepar
flo
lonicera
extract
usual
accept
patient
inject
owe
elimin
pain
discomfort
lower
cost
produc
oral
formul
clinic
effect
unsatisfactori
compar
inject
becom
one
limit
point
develop
chines
medicin
prepar
presumpt
whether
low
bioavail
oral
flo
lonicera
extract
result
poor
efficaci
whether
efficaci
could
improv
absorpt
activ
ingredi
tabl
preliminari
studi
ms
msm
data
identifi
compon
rat
plasma
oral
administr
flo
lonicera
extract
neg
mode
flo
lonicera
extract
enhanc
yet
investig
shown
fig
tabl
found
phenol
acid
flavon
saponin
found
flo
lonicera
extract
accord
hplc
figureprint
profil
shown
fig
uplcmsm
shown
fig
b
found
content
phenol
acid
flo
lonicera
extract
neochlorogen
acid
chlorogen
acid
cryptochlorogen
acid
acid
acid
mgml
respect
higher
larg
ingredi
absolut
bioavail
oral
significantli
low
unpublish
besid
content
flavon
galuteolin
mgml
lower
phenol
acid
isochlorogen
also
found
apic
load
hyperin
galuteolin
rutin
retain
apic
side
cell
transport
unpublish
conceptu
compound
pharmaceut
product
bioavail
system
circul
consid
relev
activ
marker
pharmacolog
effect
therefor
properti
main
ingredi
flo
lonicera
extract
led
us
postul
low
bioavail
phenol
acid
flo
lonicera
extract
might
result
low
efficaci
clinic
therapi
previou
studi
found
phenol
acid
instead
flavon
flo
lonicera
extract
surviv
good
posit
correl
dose
effect
antibacteri
antioxid
antivir
via
pharmacokineticpharmacodynam
pkpd
model
combin
pl
partial
least
squar
antibacteri
antioxid
antivir
activ
improv
content
phenol
acid
flo
lonicera
extract
enhanc
show
obviou
correl
dose
phenol
acid
pharmacolog
effect
besid
found
phenol
acid
especi
isochrogen
acid
flo
lonicera
extract
main
bioactiv
compon
antioxid
antivir
antibacteri
effect
spectrumact
relationship
knockoutknockin
method
wang
zhang
therefor
improv
bioavail
phenol
aicd
would
relat
pharmacolog
efficaci
improv
flo
lonicera
extract
directli
accord
previou
studi
intestin
absorpt
mechan
phenol
acid
passiv
diffus
involv
paracellular
rout
transport
mainli
govern
tight
junction
tj
konishi
kobayashi
modul
tj
absorpt
enhanc
would
enhanc
paracellular
drug
transport
salama
et
al
report
absorpt
enhanc
includ
surfact
bile
salt
chelat
agent
etc
one
promis
method
improv
bioavail
poorli
absorb
drug
oral
uchiyama
et
al
recent
demonstr
nitric
oxid
donor
polyamin
also
effect
improv
intestin
absorpt
poorli
absorb
drug
meoh
solubl
portion
flo
lonicera
extract
filter
membran
filter
result
filtrat
subject
hplc
analysi
analys
perform
use
water
allianc
hplc
system
water
corp
milford
usa
consist
quaternari
pump
solvent
manag
system
onlin
degass
autosampl
raw
data
detect
pda
acquir
process
empow
tm
softwar
hypersil
od
column
mm
thermo
scientif
waltham
usa
appli
analys
mobil
phase
compos
acetonitril
solvent
b
aqueou
phosphor
acid
vv
linear
gradient
elut
min
min
min
min
mobil
phase
flow
rate
ml
min
column
temperatur
control
c
sampl
inject
volum
l
b
uplcmsm
profil
flo
lonicera
extract
determin
phenol
acid
simultan
unpublish
fetih
et
al
howev
absorpt
enhanc
caus
damag
irrit
intestin
mucos
membran
limit
factor
clinic
use
inde
exist
almost
linear
relationship
effect
variou
absorpt
enhanc
membran
toxic
report
yamamoto
et
al
therefor
absorpt
enhanc
base
tight
junction
high
effect
low
mucos
toxic
need
investig
chitosan
natur
polym
obtain
alkalin
deacetyl
chitin
nontox
biocompat
biodegrad
abil
chitosan
enhanc
gastrointestin
gi
drug
absorpt
special
interest
gao
et
al
illum
et
al
propos
mechan
absorpt
enhanc
combin
mucoadhes
loosen
effect
tension
tight
junction
ionic
interact
neg
charg
group
glycocalix
howev
polym
solubl
acid
environ
ph
less
order
pk
valu
chitosan
restrict
applic
absorpt
enhanc
serious
exampl
reduct
teer
cell
monolay
found
apic
incub
chitosan
hydrochlorid
chitosan
glutam
ph
decreas
teer
good
measur
tight
junction
cell
observ
ph
ph
chitosan
salt
hydrochlorid
glutam
form
clear
solut
agreement
result
teer
experi
increas
transport
hydrophil
model
compound
mannitol
found
ph
incub
chitosan
salt
jonker
et
al
therefor
potenti
use
chitosan
absorpt
enhanc
basic
environ
intestin
limit
chitosan
deriv
suggest
promis
excipi
absorpt
enhanc
gi
drug
case
addit
physicochem
properti
polym
structur
desir
chitooligosaccharid
co
shown
fig
new
type
chitosan
molecular
remark
solubl
water
physiolog
ph
due
low
molecular
weight
found
content
dglucosamin
chitosan
dimer
chitosan
trimer
chitosan
tetram
chitosan
pentam
chitosan
hexam
total
respect
gao
et
al
report
effect
chitosan
oligom
intestin
absorpt
hydrophil
macromolecular
drug
fluorescein
isothiocyanatelabel
dextran
found
bioavail
could
increas
time
chitosan
dimer
wv
time
chitosan
trimer
wv
time
chitosan
hexam
wv
jejunum
besid
moder
increas
colon
absorpt
observ
presenc
chitosan
pentam
wv
dimer
wv
situ
loop
method
rat
therefor
current
studi
arm
demonstr
effect
co
intestin
absorpt
phenol
acid
flo
lonicera
extract
use
vitro
situ
vivo
model
flo
lonicera
extract
purchas
jiangyin
tianjiang
pharmaceut
co
ltd
assur
homogen
formul
prepar
consist
hatch
hplc
figureprint
profil
fig
flo
lonicera
extract
analyz
chromatograph
analysi
carri
previou
studi
chines
pharmacopoeia
commiss
chen
et
al
chen
wagner
et
al
reliabl
uhplcorbitrap
ms
system
establish
detect
prototyp
compound
flo
lonicera
extract
dose
plasma
without
co
respect
fig
voucher
specimen
deposit
laboratori
futur
refer
chlorogen
acid
galuteolin
tinidazol
use
intern
standard
purchas
nation
institut
control
pharmaceut
biolog
product
neochlorogen
acid
cryptochlorogen
acid
acid
acid
pure
purchas
sichuan
weikeqi
biotech
co
ltd
co
fig
purchas
qingdao
honghai
biotech
co
ltd
heparin
sodium
inject
purchas
changzhou
qianhong
biopharma
co
ltd
methanol
acetonitril
hplc
grade
purchas
merck
merck
germani
water
purifi
fig
product
composit
chitooligosacharid
analys
perform
use
ultrahigh
perform
liquid
chromatographi
thermo
scientif
orbitrap
mass
spectrometri
system
uhplcorbitrap
ms
mass
spectra
acquir
posit
ion
mode
within
mass
rang
mz
separ
achiev
use
welch
ultim
mm
inject
volum
use
l
mobil
phase
compos
acetonitril
solvent
b
aqueou
ammonia
vv
linear
gradient
elut
min
min
min
held
min
flow
rate
lmin
result
chromatograph
fullwidthathalfmaximum
fwhm
analyt
data
collect
resolut
scan
rate
scanss
milliq
water
purif
system
millipor
bedford
usa
chemic
reagent
analyt
grade
dulbecco
modifi
eagl
medium
dmem
fetal
bovin
serum
fb
trypsinedta
penicillinstreptomycin
nonessenti
amino
acid
obtain
gibcobri
life
technolog
usa
collagen
type
sodium
pyruv
mtt
tetrazolium
bromid
trypsin
tpck
tosylamid
phenylethyl
chloromethyl
ketontr
trypsin
purchas
sigma
chemic
co
human
colorect
cancer
cell
line
bought
cell
bank
chines
academi
scienc
madindarbi
canin
kidney
cell
line
mdck
cell
purchas
keygen
biotech
co
ltd
influenza
viru
strain
purchas
chines
academi
prevent
medicin
male
spraguedawley
sd
rat
g
suppli
experiment
anim
center
nanj
univers
chines
medicin
certif
experiment
procedur
complianc
anim
ethic
committe
nanj
univers
chines
medicin
effect
co
intestin
absorpt
chlorogen
acid
neochlorogen
acid
cryptochlorogen
acid
acid
acid
flo
lonicera
cell
cultur
high
glucos
dmem
fetal
bovin
serum
nonessenti
amino
acid
cell
cultur
humidifi
atmospher
co
c
reach
confluen
cell
harvest
trypsinedta
solut
seed
top
cc
insert
plate
surfac
area
cm
densiti
cellscm
protocol
cell
cultur
transwel
insert
similar
describ
previous
zhou
et
al
b
cell
cultur
experi
describ
previous
zhou
et
al
b
briefli
cultur
medium
aspir
cell
monolay
wash
three
time
blank
hbss
transepitheli
electr
resist
teer
valu
cell
monolay
measur
cm
monolay
incub
blank
hbss
h
c
thereaft
incub
medium
aspir
afterward
solut
contain
compound
load
onto
apic
side
donor
sampl
l
apic
side
receiv
sampl
l
basolater
side
taken
differ
time
typic
h
follow
addit
l
drug
donor
solut
donor
side
ap
l
blank
buffer
receiv
side
bl
sampl
taken
h
incub
end
transport
experi
integr
monolay
monitor
teer
valu
rat
situ
singl
pass
intestin
perfus
model
set
previous
describ
us
zhou
et
al
b
du
et
al
briefli
sd
rat
bodi
weight
g
fast
overnight
free
access
water
rat
anesthet
urethan
solut
mgkg
midlin
abdomin
incis
made
small
intestin
expos
bile
duct
ligat
order
avoid
bile
secret
perfus
region
absorpt
drug
three
intestin
section
isol
cannul
cm
long
duodenum
jejunum
ileum
segment
rins
normal
salin
c
min
wash
appear
clear
perfus
solut
drug
solvent
connect
segment
perfus
part
three
intestin
section
begin
min
circul
rate
ml
min
control
peristalt
pump
prebal
perfus
sampl
collect
solut
contain
chlorogen
acid
neochlorogen
acid
cryptochlorogen
acid
acid
acid
perfus
intestin
lumen
investig
permeabl
two
studi
compound
rat
situ
intestin
perfus
model
addit
chlorogen
acid
neochlorogen
acid
cryptochlorogen
acid
acid
acid
addit
co
also
perfus
intestin
lumen
investig
effect
chitosan
deriv
permeabl
two
studi
compound
perfus
sampl
collect
min
store
c
refriger
analysi
product
flo
lonicera
extract
dissolv
salin
without
co
give
concentr
vv
immedi
prior
drug
administr
content
neochlorogen
acid
chlorogen
acid
cryptochlorogen
acid
acid
acid
co
determin
mgml
extract
respect
male
sd
rat
g
kept
environment
control
breed
room
temperatur
c
rel
humid
week
anim
fast
h
prior
drug
administr
product
flo
lonicera
extract
without
co
prepar
dose
mlkg
dose
min
blood
collect
preintub
cathet
put
tube
heparin
sodium
inject
l
ascorb
acid
g
predetermin
time
point
subsequ
plasma
prepar
centrifug
g
min
store
c
analysi
sampl
treatment
uplcmsm
analysi
sampl
collect
vitro
situ
vivo
model
respect
describ
previous
unpublish
mdck
cell
grown
dmem
describ
previous
mehrbod
et
al
supplement
fb
penstrep
c
humidifi
incub
media
chang
two
three
time
per
week
influenza
viru
propag
mdck
cell
presenc
gml
trypsin
tpck
creat
work
stock
antivir
evalu
media
supplement
fb
suck
cell
wash
pb
treat
need
media
supplement
trypsin
tpck
ad
serum
administr
oral
flo
lonicera
extract
without
co
dosag
mgkg
ad
mdck
cell
propag
influenza
viru
cell
incub
c
h
viabil
test
measur
convers
mtt
describ
us
zhou
et
al
monolay
model
appar
permeabl
coeffici
p
app
calcul
p
app
dqdt
c
dqdt
gs
flux
rate
effect
surfac
area
cell
monolay
cm
c
gml
initi
drug
concentr
donor
chamber
rat
singlepass
intestin
perfus
situ
model
concentr
perfus
fluid
calcul
c
correct
c
pr
pr
effect
permeabl
coeffici
p
eff
calcul
p
eff
qln
c
c
correct
rl
c
correct
effluent
drug
concentr
correct
c
effluent
drug
concentr
without
correct
c
influent
drug
concentr
pr
influent
phenol
red
concentr
pr
effluent
phenol
red
concentr
q
perfus
flow
rate
r
radiu
intestin
segment
l
intestin
segment
length
inhibit
peak
concentr
c
max
time
reach
peak
concentr
max
determin
directli
plasma
concentrationtim
profil
area
curv
auc
calcul
trapezoid
method
time
zero
final
sampl
absorpt
enhanc
ratio
drug
without
enhanc
calcul
absorpt
enhanc
ratio
auc
enhanc
auc
control
without
enhanc
statist
signific
p
app
p
eff
valu
pharmacokinet
paramet
inhibit
rate
index
obtain
variou
treatment
group
estim
analysi
varianc
student
ttest
oneway
anova
p
valu
less
consid
significantli
differ
data
express
mean
sd
effect
co
p
app
valu
phenol
acid
apicaltobasolater
apbl
direct
vitro
monolay
model
shown
fig
co
low
medium
high
concentr
caus
signific
concentrationdepend
increas
p
app
valu
neochlorogen
acid
chlorogen
acid
cryptochlorogen
acid
acid
acid
compar
control
group
p
highest
p
app
valu
neochlorogen
acid
chlorogen
acid
cryptochlorogen
acid
acid
acid
increas
cm
cm
cm
cm
cm
addit
wv
co
shown
fig
co
led
dosedepend
p
eff
valu
neochlorogen
acid
chlorogen
acid
cryptochlorogen
acid
duodenum
ileum
jejunum
co
low
dose
yield
maximum
absorpt
p
eff
valu
acid
duodenum
ileum
show
dosedepend
manner
jejunum
co
moder
concentr
reach
maximum
absorpt
besid
co
gave
p
eff
valu
acid
dosedepend
manner
duodenum
jejunum
moder
dose
made
acid
absorb
maxim
ileum
result
indic
intestin
absorpt
phenol
acid
enhanc
co
meanwhil
absorpt
enhanc
effect
phenol
acid
might
satur
differ
intestin
site
shown
fig
ng
minml
ng
minml
ng
minml
respect
addit
co
dosag
mgkg
although
found
previou
studi
co
dosag
mgkg
could
result
maximum
enhanc
absorpt
polyphenol
compon
like
chlorogen
acid
unpublish
therefor
find
indic
mgkg
co
would
promis
enhanc
improv
bioavail
phenol
acid
flo
lonicera
extract
rat
shown
fig
antivir
model
built
success
inhibit
rate
co
group
signific
compar
pb
group
although
remark
increas
inhibit
rate
valu
administr
oral
mgkg
ribavirin
posit
control
howev
differ
antivir
activ
flo
lonicera
extract
without
co
signific
fig
b
inhibit
rate
flo
lonicera
extract
co
dosag
mgkg
higher
without
co
indic
pharmacolog
effect
antivir
effect
flo
lonicera
extract
could
significantli
improv
addit
co
plasma
concentrationtim
profil
phenol
acid
flo
lonicera
extract
equival
mgkg
neochlorogen
acid
mgkg
chlorogen
acid
mgkg
cryptochlorogen
acid
mgkg
acid
mgkg
acid
co
administr
rat
gastrointestin
vivo
pharmacokinet
studi
result
express
mean
sd
experi
present
studi
found
fig
tabl
peak
detect
dose
plasma
without
co
control
plasma
compar
chemic
profil
dose
plasma
control
plasma
neg
ion
mode
among
peak
phenol
acid
flavonoid
aglycon
contain
peak
also
appear
ms
spectra
flo
lonicera
extract
indic
compon
may
absorb
rat
plasma
origin
form
result
consist
previou
report
flavonoid
glucosid
like
galuteolin
hyperin
tabl
pharmacokinet
paramet
chlorogen
acid
neochlorogen
acid
cryptochlorogen
acid
acid
acid
rat
oral
administr
flo
lonicera
extract
without
addit
co
mean
sd
n
tmax
hyperosid
rutin
well
absorb
cell
suggest
flavonoid
glycosid
need
transform
flavonoid
aglycon
absorb
plasma
fig
real
activ
ingredi
flavonoid
may
flavonoid
aglycon
flavonoid
glycosid
howev
flavonoid
glycosid
vivo
quantit
assess
well
illustr
fig
meanwhil
shown
fig
treatment
flo
lonicera
extract
co
improv
mdck
cell
viabil
better
influenza
viru
propag
evid
support
hypothesi
phenol
acid
consid
one
import
marker
compound
control
pharmacolog
flo
lonicera
extract
also
found
absorpt
enhanc
effect
co
improv
intestin
absorpt
phenol
acid
affect
concentr
maxim
absorpt
enhanc
effect
co
observ
dosag
mgkg
higher
dose
gao
et
al
report
absorpt
enhanc
effect
chitosan
hexam
depend
concentr
absorpt
enhanc
effect
almost
satur
wv
situ
loop
method
therefor
present
result
consist
previou
report
chitosan
optim
concentr
show
greatest
absorpt
enhanc
effect
improv
intestin
absorpt
phenol
acid
flo
lonicera
extract
although
type
chitosan
differ
present
studi
also
demonstr
absorpt
phenol
acid
flo
lonicera
extract
improv
greatest
also
safeti
gastrointestin
co
dosag
mgkg
meanwhil
thanou
et
al
thanou
et
al
show
effect
low
viscos
grade
mononcarboxymethyl
chitosan
lmcc
high
low
viscos
grade
nsulfonaton
ocarboxymethylchitosan
absorpt
low
molecular
weight
heparin
lmwh
found
auc
valu
increas
time
respect
intraduoden
administr
therefor
chitosan
deriv
absorpt
enhanc
need
investig
order
improv
pharmacolog
effect
flo
lonicera
extract
better
